Expression of miR-21-5p in oral submucosal fibrotic cancerous cells and bioinformatics analysis#br#
HU Zhaoyong1 TAN Jin2 CHEN Ming2 YANG Qingze3 LIU Yanli3
1.Anatomy Experiment Center, School of Medicine, Hunan University of Chinese Medicine, Hunan Province, Changsha 410208, China;
2.Department of Stomatology, the First Affiliated Hospital of Hunan University of Chinese Medicine, Hunan Province, Changsha 410007, China;
3.School of Medicine, Hunan University of Chinese Medicine, Hunan Province, Changsha 410208, China
Abstract：Objective To observe the expression of miR-21-5p in oral submucosal fibrotic cancerous cells and its bioinformatics analysis. Methods The primary oral mucosal epithelial cells of rats were divided into experimental group and normal control group. The experimental group was induced with areca nut extract of 50 μg/ml, and the model of oral submucosal fibrotic cancerous cells was established. RT-qPCR was used to detect the expression of miR-21-5p in the two groups, and 30 databases including miRDB and TargetScan were used to predict the target genes of hsa-miR-21-5p, and functional enrichment analysis and signal pathway enrichment analysis were performed. Results RT-qPCR results showed that the expression of miR-21-5p in the experimental group was higher than that in the control group, and the difference was highly statistically significant (P ＜ 0.01). The results of bioinformatics analysis showed that Smad7, PLAG1, and TGF-β1 ranked the top three in the comprehensive score of miR-21-5p target gene prediction. MiR-21-5p target genes were mainly enriched in cellular macromolecular metabolism, intracellular organelles, and other components and protein enzyme aggregation, while the signaling pathways were significantly enriched in MAPK and other signaling pathways. Conclusion MiR-21-5p is highly expressed in oral submucosal fibrotic cancerous cells. Smad7 may influence oral submucosal fibrotic carcinogenesis by mediating the cross-dialogue between miR-21-5p and TGF-β.
[1] Li X，Wu X. MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7 [J]. OncoTargets Ther，2018，11（11）：8445-8454.
[2] Wu X. Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis [J]. Iran J Public Health，2020，49（1）：21-29.
[3] Singh P，Srivastava AN，Sharma R，et al. Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma [J]. Asian Pac J Cancer Prev，2018，19（4）：1053-1057.
[4] Yang HW，Yu CC，Hsieh PL，et al. Arecoline enhances miR-21 to promote buccal mucosal fibroblasts activation [J]. J Formos Med Assoc，2021，120（4）：1108-1113.
[5] Tejasvi M，Bangi BB，Geetha P，et al. Estimation of serum superoxide dismutase and serum malondialdehyde in oral submucous fibrosis：a clinical and biochemical study [J]. J Cancer Res Ther，2014，10（3）：722-725.
[6] Hebbar P，Sheshaprasad R，Gurudath S，et al. Oral submucous fibrosis in India：Are we progressing？[J]. Indian J Cancer，2014，51（3）：222-226.
[7] Garg N，Rm R. Morphometric analysis of epithelial thickness and blood vessels in different grades of oral submucous fibrosis [J]. Malays J Pathol，2014，36（3）：189-193.
[8] Dai JP，Chen XX，Zhu DX，et al. Panax notoginseng saponins inhibit areca nut extract-induced oral submucous fibrosis in vitro [J]. J Oral Pathol Med，2014，43（6）：464-470.
[9] Zhou S，Guo F，Li L，et al. Multiple logistic regression analysis of risk factors for carcinogenesis of oral submucous fibrosis in mainland China [J]. Int J Oral Maxillofac Surg，2008，37（12）：1094-1098.
[10] He Q，Chen Z，Cabay RJ，et al. microRNA-21 and microRNA-375 from oral cytology as biomarkers for oral tongue cancer detection [J]. Oral Oncol，2016，57（1）：15-20.
[11] Dioguardi M，Caloro GA，Laino L，et al. Circulating miR-21 as a Potential Biomarker for the Diagnosis of Oral Cancer：A Systematic Review with Meta-Analysis [J]. Cancers（Basel），2020，12（4）：936-936.
[12] Li J，Yong H，Huang Y. Microrna-21：A Central Regulator of Fibrotic Diseases Via Various Targets [J]. Curr Pharm Des，2015，21（17）：2236-2242.
[13] Xu X，Zheng L，Yuan Q，et al. Transforming growth factor-β in stem cells and tissue homeostasis [J]. Bone Res，2018，6（1）：2-5.
[14] Shi X，Young CD，Zhou H，et al. Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts [J]. Biomolecules，2020，10（12）：1666-1667.
[15] Rai A，Ahmad T，Parveen S，et al. Expression of transforming growth factor beta in oral submucous fibrosis [J]. J Oral Biol Craniofac Res，2020，10（2）：166-170.
[16] Papageorgis P，Stylianopoulos T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery（review） [J]. Int J Oncol，2015，46（3）：933-943.
[17] Fabregat I，Fernando J，Mainez J，et al. TGF-beta signaling in cancer treatment [J]. Curr Pharm Des，2014，20（17）：2934-2947.
[18] Hiroshi S. MicroRNA Control of TGF-β Signaling [J]. Int J Mol Sci，2018，19（7）：1901-1907.
[19] Butz H，Rácz K，Hunyady L，et al. Crosstalk between TGF-β signaling and the microRNA machinery [J]. Trends Pharmacol Sci，2012，33（7）：382-393.
[20] Wu K，Ye C，Lin L，et al. Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT[J]. Clin Sci（Lond），2016，130（16）：1469-1480.
[21] Tan G，Xu F，Song H，et al. Identification of TRIM14 as a Type I IFN-Stimulated Gene Controlling Hepatitis B Virus Replication by Targeting HBx [J]. Front Immunol，2018，9（1）：1872-1876.
[22] 邓羊羊，葛善飞，余燕青，等.肝纤维化相关细胞信号转导通路及潜在治疗策略[J].临床肝胆病杂志，2020，36（5）：1141-1145.
[23] Zhou X，Xiong J，Lu S，et al. Inhibitory Effect of Corilagin on miR-21-Regulated Hepatic Fibrosis Signaling Pathway [J]. Am J Chin Med，2019，47（7）：1541-1569.
[24] 张诗琬，喻雪琴，陈芳，等.外泌体microRNA的生物学特征及在肝纤维化发生发展中的作用[J].临床肝胆病杂志，2020，36（9）：2083-2086.
[25] Yuan J，Chen H，Ge D，et al. Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7 [J]. Cell Physiol Biochem，2017，42（6）：2207-2219.
[26] Li Q，Zhang D，Wang Y，et al. MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation [J]. Sci Rep，2013，3（1）：2038-2042.
[27] Hu X，Xiong H，Wang W，et al. Study on the expression and function of smad family member 7 in oral submucous fibrosis and oral squamous cell carcinoma [J]. Arch Oral Biol，2020，112（1）：104687-104692.
京公网安备 11010502046598号